Genotek Genotek

"Genotek" is the international company founded in Russia in 2010 by Artem Elmuratov, Valery Ilyinsky and Kirill Petrenko. Offices of the company are located in Russia, Kazakhstan, the USA and in Cyprus. Representatives RuStarsVentures, Rusagro agroholding and also a number of private investors invested more than 2.5 million dollars in "Genotek".

Services

The laboratory of the Genetico Center is registered in an information and analytical system of the Russian Scientific Fund (RSF) as a world-class infrastructure facility. Also the Center obtained accreditation of Skolkovo Foundation as the Center of Collective Use (CCU). Genetico provides to residents of the Biomedical cluster services in sequencing of a genome (NGS), the analysis of single cages and their specific activity, the chromosomal micromatrix analysis and also conducts genetic researches on search of mutations and bioinformatichesky researches.

Genetico laboratories are equipped with sequenators and the robotic equipment of the last generation and allow to perform the advanced genetic researches necessary for medicine, genomics and the proteomiki.

Genotek has one of the genetic laboratories, largest in Eastern Europe, in which executes researches for private clients of clients and medical clinics of 71 countries of the world. All process of accomplishment of analyses and data storage are localized in Russia. The largest medical institutions of Russia, including the Russian oncological scientific center, the Russian children's clinical hospital, the First Moscow state medical university and others are among clients of Genotek. Cooperation with clinics allows to specify diagnoses, to select effective treatment and to save lives of people.

2020

Genotek attracted $4 million investments, including from "Yandex"

In December, 2020 it became known that the Genotek company attracted a round of investments for $4 million. The company of "Yandex" became the leading and new investor of a round. The representative of "Yandex" will join Genotek the board. Founders of the company Artem Elmuratov and Ilyinsky Valery retained control.

As well as other shareholders of Genotek, "Yandex" will not get access to technological solutions of the company and data of users. Also change of privacy policy which assumes a total ban on transfer of any personal data of clients to someone, including shareholders of the company is not planned. Data on an exact share and on the one who will join the board are not published.

The Russian medico-genetic center Genotek attracted $4 million. Among investors — "Yandex"

The received investments will be directed to creation of new more available products and development of services which will give the chance to use results of genetic tests in many life situations, including the personalized recommendations about treatment of diseases, to health insurance, a power supply and studying of history of family. Also means will go for development of scientific, medical and commercial base of the company, the representative in a conversation with TAdviser explained it.

Our commands work in close contact concerning delivery, on algorithms of data processing and in automation of communication with clients already now. We see joint interest and in other areas  — development of telemedicine services, education  — the founder of a startup Valery Ilyinsky told, commenting on the transaction.

According to SPARK-Interfax, by December 24, 2020 Ilyinsky possesses 80% in Genotek LLC, Genotek Holding LLC has another 20%. This company, in turn, the Cyprian Cleome Holdings ltd owns.

For Genotek it is already the third round of investments, and for "Yandex" it is the first project in the field of genetic researches. According to the CEO of "Yandex" in Russia Elena Bunina, the field of medical genetics only begins to develop, and at Genotek, according to her, high potential of growth. At the same time the company already develops the project in the field of medicine in general — it possesses telemedicine service " Yandex.health ".

The co-founder of biomedical holding "Atlas" Sergey Musiyenko in a conversation with Vedomosti highly appreciated the potential of growth both Russian market of genetic researches, and world. According to him, only consumer segment of this industry assuming carrying out researches for private clients without appointment of the doctor (tests on predispositions, genealogy), annually grows in Russia approximately for 50%. Such indicator is connected with the fact that a niche new in itself and develops only at the expense of local players, Musiyenko says. At the same time he notes that the Russian market of genetic researches makes less than 1% of world as, according to him, in other countries this industry is developed much better.^[1]

Production of highly sensitive PTsR-tests

At the beginning of 2020 the company developed and started production of highly sensitive PTsR-tests for diagnosis of a new koronavirusny infection which are delivered in laboratory of Russia and the CIS countries. Genotek became the participant of the COVID-19 Host Genetics international consortium which purpose — to reveal genetic factors of resistance to a new koronavirusny infection.

2017: Investments from Pharmstandard

Million dollars of the investment capital entered at the beginning of 2017 Pharmstandard to the medico-genetic center "Genotek", and the list of directors was replenished with Victor Haritonin.

The investment capital intends for development of the direction of a research in the genetic and pharmaceutical industries. Plans at "Genotek" ambitious — development of technologies of molecular and genetic diagnostics and also carrying out therapeutic intervention using the personalized medicines which the company intends to put in production.

"Partnership of "Genotek" and Pharmstandard will be directed to creation of a full stroke in the field of medicine: from development and production of medicines before the personalized approaches in therapy" — the CEO and the co-founder of "Genotek" Ilyinsky Valery noted.

Representatives of Pharmstandard consider that the investment in this industry will bring big benefit as the pharmaceutical sphere is in Russia now on initial stage of development: market size amounts only 100 million rubles a year. At the global level the markets of genetic analyses and diagnostics and the personalized medicine are one of fast-growing segments of economy.

2010: Foundation of the company

The Genotek company is founded in 2010 by graduates of Lomonosov Moscow State University Valery Ilyinsky, Artem Elmuratov and Kirill Petrenko. Data of the DNA researches conducted by the company allow to reveal the probability of developing of diseases, to define origin, to find relatives, together with the doctor to develop the personal program of trainings and a power supply and also to make the diagnosis and to pick up effective therapy.